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Summary
Lysosomal storage diseases (LSD) form a group of inher-
ited metabolic disorders caused by dysfunction of one of the
lysosomal proteins, resulting in the accumulation of certain
compounds. Although these disorders are among ﬁrst genetic
diseases for which speciﬁc treatments were proposed, there
are still serious unsolved problems that require development
of novel therapeutic procedures. An example is neuronopathy,
which develops in most of LSD and cannot be treated efﬁ-
ciently by currently approved therapies. Recently, a new
potential therapy, called gene expression-targeted isoﬂavone
therapy (GET IT), has been proposed for a group of LSD
named mucopolysaccharidoses (MPS), in which storage of
incompletely degraded glycosaminoglycans (GAGs) results in
severe symptoms of virtually all tissues and organs, including
central nervous system. The idea of this therapy is to inhibit
synthesis of GAGs by modulating expression of genes coding
for enzymes involved in synthesis of these compounds. Such a
modulation is possible by using isoﬂavones, particularly genis-
tein, which interfere with a signal transduction process neces-
sary for stimulation of expression of certain genes. Results of
in vitro experiments and studies on animal models indicated a
high efﬁciency of GET IT, including correction of behavior
of affected mice. However, clinical trials, performed with soy
isoﬂavone extracts, revealed only limited efﬁcacy. This caused
a controversy about GET IT as a potential, effective treat-
ment of patients suffering from MPS, especially neurono-
pathic forms of these diseases. It this critical review, I pres-
ent possible molecular mechanisms of therapeutic action of
isoﬂavones (particularly genistein) and suggest that efﬁcacy of
GET IT might be sufﬁciently high when using relatively high
doses of synthetic genistein (which was employed in experi-
ments on cell cultures and mouse models) rather than low
doses of soy isoﬂavone extracts (which were used in clinical
trials). This proposal can be tested in double-blinded,
placebo-controlled clinical trials.  2012 IUBMB
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INTRODUCTION
Lysosomal storage diseases (LSDs) are inherited metabolic
disorders caused by mutations in genes coding for: (i) proteins
that hydrolyze compounds that are transported into the lyso-
somes or appear in the lysosomes as a result of fusion with
autophagic vacuoles or endocytic vesicles, (ii) proteins that are
needed for the activity of the hydrolases mentioned above, such
as the saponins, (iii) proteins that are needed for lysosomal
transport (1, 2). There are more than 50 different LSDs identi-
ﬁed to date. Defects of functions of the lysosomal proteins or
their absence cause the accumulation of one or more speciﬁc
compounds such as glycogen, glycosaminoglycans (GAGs),
sphingolipids, cholesterol ester, and others in lysosomes and
sometimes in the entire cell. This leads to dysfunctions of cells,
tissues, and organs. Attempts are made to treat lysosomal stor-
age diseases by enzyme replacement and substrate reduction
therapies, as well as other potential therapies which are being
developed (2–6).
Mucopolysaccharidoses (MPS) form a group of LSD in
which accumulation of GAGs occurs (3). There are 11 types
and subtypes of MPS, classiﬁed depending on the kind of lack-
ing or deﬁcient enzyme and the kind of accumulated GAG(s)
(Table 1). All MPS types are severe diseases, with average life
span between one and two decades. In most of them (excluding
types IV and VI), particularly those in which heparan sulfate
(HS) is the sole or one of accumulated GAG(s), neuronopathy
develops, which includes mental deterioration, behavioral
changes and other severe neurological symptoms (ref. 4 and
references therein). MPS are progressive diseases; affected
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patients are born usually without any obvious symptoms, but
they appear within ﬁrst months or years of life and become suc-
cessively more and more severe. In most patients, the life span
is signiﬁcantly shortened, with death occurring during the ﬁrst
or second decade.
THERAPEUTIC OPTIONS FOR MPS
Because MPS are caused by a lack or dysfunction of certain
enzymes involved in degradation of GAGs, one obvious thera-
peutic strategy is to provide the lacking enzyme to cells of
patients. This idea appeared promising in LSD, because a bio-
chemical signal, a phospho-mannose, for transportation of some
lysosomal enzymes to their target localization (lysosomes) has
been discovered, and the possibility of uptake of such enzymes
by cells from extracellular ﬂuids has been demonstrated (for
reviews, see refs. 2 and 3). This knowledge was used to de-
velop enzyme replacement therapy (ERT), in which a recombi-
nant enzyme is administered intravenously and can be distrib-
uted to lysosomes located in various cells (5). Another way to
deliver an active enzyme to cells of MPS patients is to trans-
plant bone marrow or hematopoietic stem cells, which excrete a
portion of produced lysosomal proteins, thus, the enzymes can
be recognized by mannose-6-phosphate receptors on MPS cells’
membranes and transported to lysosomes (6). Transplantation
therapy can only be effective when the procedure is performed
during ﬁrst 2 years of life, and only in some MPS types; for
example, positive effects were detected in MPS I but not in
MPS III patients (6).
ERT is considerably more efﬁcacious than bone marrow
transplantation; however, improvement in clinical parameters
was observed only in tissues other than the central nervous sys-
tem. This is caused by the fact that a recombinant enzyme,
when administered intravenously, cannot cross the blood-brain-
barrier (5, 6).
Gene therapy is another option for treatment of MPS and is
predicted to be the most efﬁcient way to cure genetic diseases
(7). However, despite many years of studies performed in dif-
ferent laboratories, it is still a therapy under development (7).
Because of problems mentioned above, there is still a need
for novel therapies, suitable to treat patients suffering from
MPS, especially from neurological symptoms. Understanding of
molecular mechanisms of the disease led to proposals for alter-
native methods of treatment of MPS patients (8). Among them,
Table 1
Mucopolysaccharidoses: deﬁcient enzymes, corresponding genes, and stored GAGs
MPS typea Syndrome name (OMIM ID)b Enzyme (UniProt no.)c Gene and its localization Stored GAG(s)d
MPS I Hurler (607014) a-L-iduronidase (P35475) IDUA, 4p16.3 HS, DS
Scheie (607016)
Hurler-Scheie (607015)
MPS II Hunter (309900) Iduronate 2-sulfatase (P22304) IDS, Xq28 HS, DS
MPS IIIA Sanﬁlippo A (252900) N-sulfoglucosamine sulfohydrolase
(Heparan N-sulfatase) (P51688)
SGSH, 17q25.3 HS
MPS IIIB Sanﬁlippo B (252920) a-N-actylglucosaminidase (P54802) NAGLU, 17q21 HS
MPS IIIC Sanﬁlippo C (252930) Acetyl-CoA:a-glycosaminide
acetyltransferase (Q68CP4)
HGSNAT, 8p11.1 HS
MPS IIID Sanﬁlippo D (252940) N-acetylglucosamine 6-sulfatase
(P15586)
GNS, 12q14 HS
MPS IVA Morquio A (253000) N-acetylgalactosaminide 6-sulfatase
(P34059)
GALNS, 6q24.3 KS, 6-CS
MPS IVB Morquio B (253010) b-galactosidase (P16278) GLB1, 3p21.33 KS
MPS VI Maroteaux-Lamy (253200) N-acetylgalactosamine 4-sulfatase
(arylsulfatase B) (P15848)
ARSB, 5q11–13 DS
MPS VII Sly (253220) b-glucuronidase (P08236) GUSB, 7q21.11 HS, DS, 4,6-CS
MPS IX Natowicz (601492) Hyaluronoglucosaminidase-1
(hyaluronidase) (Q12794)
HYAL1, 3p21.3 HA
aThe syndroms included in MPS I are recognized solely according to clinical features, as deﬁciency of the same enzyme occurs in all MPS I patients. The
names MPS V and MPS VIII are no longer used (MPS V has been recognized as a clinical variant of MPS I, and MPS VIII has been originally diagnosed
in a patient who apparently suffered from two other MPS types simultaneously).
bThe ID numbers of Online Mendelian Inheritance in Man (OMIM) are provided (see: http://www.ncbi.nlm.nih.gov/omim).
cThe names of enzymes are provided according to recommendations of International Union of Biochemistry and Molecular Biology (IUBMB), and alterna-
tive names are included if frequently used in literature. The numbers are according to UniProt (http://www.uniprot.org).
dThe abbreviations of glycosaminoglycans (GAGs) are: 4,6-CS; chondroitin-4,6-sulfate; 6-CS, chondroitin-6-sulfate; DS, dermatan sulfate; HA, hyaluronic
acid; HS, heparan sulfate; KS, keratan sulfate.
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there is substrate reduction therapy (SRT), which decreases the
efﬁciency of synthesis of compounds (GAGs in the case of
MPS) that cannot be degraded in cells of affected organism (9).
Impairment of GAG synthesis can be achieved by various ways.
One example is the use of rhodamine B ([9-(2-carboxyphenyl)-
6-diethylamino-3-xanthenylidene]-diethylammonium chloride).
This compound was found to impair GAG production in cul-
tured cells of MPS type IIIA and MPS type VI patients,
decreasing GAG storage (10). GAG levels were reduced in tis-
sues of MPS type IIIA mice treated with 1 mg/mL rhodamine
B, in which behavioral improvement was also evident (11).
However, rhodamine B appears to be toxic for humans, particu-
larly it may be harmful when swallowed or injected, and may
cause irritation of skin, eyes and respiratory tract (for a review,
see ref. 9). Although it was demonstrated recently that trans-
generational exposure to low levels of rhodamine B did not
adversely affect litter size and liver function in murine MPS
type IIIA model (12), it is not known whether low doses of this
compound could be effective in treatment of patients suffering
from MPS.
Another possibility to reduce efﬁciency of GAG synthesis is
to decrease levels of enzymes involved in this process. This can
be achieved by the use of either siRNA or shRNA, as demon-
strated recently (13, 14). However, the problems with efﬁcient
delivery of RNA molecules to cells, especially to the central
nervous system, and with their stability, must be overcome
before siRNA or shRNA can be used for therapies of genetic
diseases, including MPS (15, 16).
GENE EXPRESSON-TARGETED ISOFLAVONE THERAPY
Limitations of the use of either rhodamine B or RNAi-based
procedures indicated that another form of SRT should be devel-
oped to address the problem of efﬁcient treatment of neurono-
pathic MPS types. As GAGs are composed of monosaccharides
(like xylose, galactose at the reducing end of the polymer where
it is connected to the serine or its protein, and others) that are
used in various biochemical pathways, it is assumed that any
chemical analogue of such compounds, blocking activity of cer-
tain GAG-synthesizing enzyme, might have severe adverse
effects due to interference with other biochemical reactions.
Theoretically, inhibitors of glucuronyl C5 epimerase, the
enzyme that produces iduronic acid in HS, could be developed
as potential safe drugs. However, to my knowledge, no success-
ful studies involving such a strategy were performed to date.
Therefore, another option had to be found.
Rationale
The ﬁrst report suggesting a possibility for development of
gene expression-targeted isoﬂavone therapy (GET IT; although
this name was not used at that time) was based on analysis of
genetic regulation of GAG turnover (17). As both synthesis and
degradation of GAGs depends on activities of many enzymes, it
was assumed that any variations in efﬁciency of expression of
genes coding for proteins involved in GAG synthesis should
inﬂuence both severity and dynamics of progression of MPS
disease. If so, determination of efﬁciency of GAG synthesis, in
combination with measurement of residual activity of the deﬁ-
cient GAG-degrading enzyme, might provide a basis for predic-
tion of severity and clinical progress of MPS (17) (which was,
in fact, conﬁrmed experimentally a few years later, see ref. 18).
Apart from this, such a hypothesis led to the idea that inhibition
of expression of genes coding for enzymes necessary for GAG
synthesis might allow us to achieve a new balance between efﬁ-
ciency of GAG synthesis and degradation, disturbed in cells of
MPS patients (17). The question was what compound(s) can
both decrease efﬁciency of expression of such genes and cross
the blood-brain-barrier? Analysis, of previous articles on basic
mechanisms of regulation of GAG synthesis (in fact, published
many years ago), suggested that genistein (5,7-dihydroxy-3-(4-
hydroxyphenyl)-4H-1-benzopyran-4-one) (Fig. 1), a compound
belonging to the group of isoﬂavones, can be such a molecule.
Addition of epidermal growth factor (EGF) to cultures of
human cells caused an increase of GAG synthesis efﬁciency
(19), and genistein was described as inhibitor of EGF receptor
kinase activity (20). Moreover, genistein was found to be able
to cross the blood-brain-barrier in rats with efﬁciency of about
10% (21). Thus, it was reasonable to test whether genistein can
decrease production and storage of GAGs in MPS cells.
Experiments with Cell Cultures
The ﬁrst experiments on effects of genistein on GAG pro-
duction and storage were performed in cultured ﬁbroblasts
derived from patients suffering from MPS types I, II, IIIA, and
IIIB (22). In all tested cultures, this isoﬂavone signiﬁcantly
impaired GAG synthesis efﬁciency, with a dose-response corre-
lation. A considerable reduction in storage was determined by
both biochemical reactions and electron microscopic analyses.
These results were encouraging, and a potential treatment of
MPS with genistein has been named GET IT, according to puta-
tive mechanism of action of this isoﬂavone on GAG synthesis
(22). Subsequent studies conﬁrmed that genistein-mediated inhi-
bition of EGF receptor autophosphorylation, and resultant inefﬁ-
cient signal transduction, is the main, although not necessary
the only one, cause of this phenomenon (23).
Recent reports indicated that genistein is not the only isoﬂa-
vone able to reduce efﬁciency of GAG synthesis. Other isoﬂa-
vones (formononetin, daidzein, biochanin A, and glycitein)
Figure 1. Structure of genistein (40,5,7-trihydroxyisoﬂavone or
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one).
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were also effective in decreasing GAG storage in ﬁbroblasts
derived from patients suffering from MPS types IIIA and VI
(24). Interestingly, combinations of various isoﬂavones were
more effective in reducing GAG storage than any one single
isoﬂavone (24). This unexpected phenomenon of synergistic
action of isoﬂavones might be explained by results of recent
experiments, which indicated that other ﬂavonoids, unlike genis-
tein, can decrease efﬁciency of GAG synthesis in reactions in-
dependent on EGF receptor autophosphorylation (25). There-
fore, one can propose that there are different mechanisms of in-
hibition of GAG production by genistein and other isoﬂavones
(or ﬂavonoids), thus, effects of mixtures of these compounds
may be additive.
Studies on Animal Models
Results of in vitro experiments encouraged researchers to
perform studies on animal models. To date, mouse models of
MPS types II and IIIB were tested. In studies on MPS type II
mice, treated with soy isoﬂavone extract at doses corresponding
to either 5 or 25 mg genistein per 1 kg of body weight daily,
several important effects were observed (26). Urinary GAG lev-
els were reduced after 10 weeks of the treatment, as were GAG
levels in tissue samples from liver, spleen, kidney, and heart.
Importantly, in some animals, decreased GAG deposits in brain
were observed after genistein treatment (26).
MPS type IIIB mice were treated with synthetic genistein in
both short-term (8 weeks) and long-term (9 months) experi-
ments. The short-term experiment indicated that genistein was
safe for animals at doses ranging from 5 to 160 mg per 1 kg of
body weight daily (27). A signiﬁcant reduction in GAG storage
in various peripheral tissues was found, and the changes
depended on the genistein dose used (27). However, no statisti-
cally signiﬁcant changes in GAG levels in brain were observed
after treatment of animals for 8 weeks (27).
Long-term experiment with MPS type IIIB mice was focused
on changes in central nervous system. Contrary to the short-
term experiment, treatment of these animals with genistein for 9
months at the dose of 160 mg/kg/day resulted in signiﬁcant
(although far from complete) reduction of GAG storage in brain
(28). Moreover, secondary symptoms of MPS, such as inﬂam-
matory reactions, ganglioside storage, and reduced expression
of VAMP2 were considerably improved in genistein-treated
MPS type IIIB mice compared to untreated controls (28).
Importantly, nine different behavioral parameters that were dra-
matically worsened in untreated animals, have been completely
corrected (relative to wild-type mice) after 9-month treatment
with genistein at 160 mg/kg/day (28). It is surprising that
incomplete reduction of GAG storage and other biochemical
and histological parameters correlated with complete correction
of behavior of mice. But such results are compatible with the
course of development of the disease in children, where symp-
toms are absent for several months or even a few years, despite
unquestioned accumulation of GAGs and secondary storage
materials ongoing since birth. This suggests that signiﬁcant ther-
apeutic effects can be obtained without complete clearance of
GAG from patient’s cells and tissues.
It is interesting that both animal models used in studies on
GET IT for MPS consisted of null mutants (26–28). Therefore, a
molecular mechanism for genistien-mediated reduction in GAG
storage must not be restricted to residual activity of the deﬁcient
enzyme, which in combination with impaired synthesis could
lead to a decrease in amount of already accumulated material, as
suspected previously for any kind of SRT (9). One may speculate
that dilution of already accumulated GAGs and/or actions of
unspeciﬁc GAG endoglycosidases, like heparanase, may signiﬁ-
cantly contribute to GAG clearance in MPS cells subjected to
GET IT. These mechanisms might act due to either growth and
divisions of affected cells or bypassing the inhibited step of GAG
degradation. Irrespective of the actual mechanism, experiments
on animals indicated that GET IT might be potentially efﬁcacious
not only for MPS patients in which residual enzyme activity is
detectable, but also for those bearing two null alleles of the
affected gene and producing no residual activity of its product.
Clinical Trials
Successes in studies on GET IT with cell cultures and ani-
mal models were rapidly followed by pilot clinical trials. This
was justiﬁed by the fact that genistein is a natural product (pres-
ent in many plants) and appears to be safe. It is available in soy
isoﬂavone extracts that are widely sold in health-food stores.
SRT, including GET IT, has been called a new hope for
patients suffering from neuronopathic forms of LSD (29). This
increased the pressure for testing this therapy in severe, debili-
tating and actually deadly diseases, like MPS.
The ﬁrst pilot clinical study, in which GET IT has been tested,
was performed on 10 pediatric patients suffering from MPS types
IIIA and IIIB (30). In this open-label trial, a soy isoﬂavone
extract was used at the dose corresponding to 5 mg genistein per
1 kg of body weight daily. After 1 year treatment, following
effects were observed: (i) urinary HS (the GAG accumulated in
MPS type III) level decreased signiﬁcantly (from the mean value
of 22 to 16 mg per 1 g of creatinine; P 5 0.028), (ii) hair mor-
phology (a parameter described previously as a potential bio-
marker in assessment of efﬁcacy of anti-MPS treatment, see refs.
31 and 32) was signiﬁcantly improved (from the mean value of
hair dysmorphology of 1.9 to 0.9; P 5 0.012), and (iii) scores in
a cognitive test were higher than at baseline (the mean score at
baseline was 16.5, and it increased to 19.7 after 12 months of the
treatment; P 5 0.012). These results might look promising,
nevertheless, it is necessary to note that although statistical sig-
niﬁcance was achieved in analyses of differences between results
measured at baseline and after 12 months of the treatment, the P
values calculated in particular tests were not spectacular. More-
over, one should note that clinical improvements were observed
in 7, 8 and 8 patients (out of 10 tested), depending on the tested
parameters (30).
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A 2-year follow-up study, which included eight patients,
was performed and its results has been published recently
(33). Cognitive functions and behavior were assessed, as
symptoms related to functions of central nervous system are
the most severe ones in MPS type III. Among eight patients,
in which GET IT was used for 3 years (1 year clinical trial
and 2-year follow-up) at the genistein dose of 5 mg/kg/day, an
improvement of cognitive functions in seven patients and sta-
bilization in one patient were assessed during the ﬁrst year,
while after the third year (2-year follow-up) further improve-
ment was observed in two patients, stabilization in three
patients and some deterioration in three patients. Monitoring
of general and behavioral symptoms revealed improvement in
all patients after the ﬁrst year of the treatment, further
improvement in ﬁve patients, and deterioration in three
patients during the next 2 years. These results suggest a gen-
eral stabilization of patients during 3 year GET IT; however,
variability in response to this treatment among patients is
obvious. One should note that even in patients that deterio-
rated during the therapy, the progress of the disease was
slower than that expected on the basis of our general knowl-
edge on MPS type III disease.
Another open-label clinical trial with MPS type III patients,
in which GET IT was used, has been performed with the
employment of different tests (34). The soy isoﬂavone extract
at the dose corresponding to 5 mg/kg/day genistein was used,
like in studies described in previous paragraphs, however, apart
from measuring urinary GAG levels and assessing hair mor-
phology, another test was employed to assess the level of dis-
ability. In this trial, a decrease in frequency of infections and
gastrointestinal symptoms and improvement in skin texture and
hair morphology were noted (34). However, urinary GAG levels
did not change signiﬁcantly and disability was not decreased.
This might suggest a low efﬁcacy of the treatment, which is in
contrast to conclusions proposed on the basis of other studies
(compare refs. 30, 33, and 34). One possible explanation of this
discrepancy could be a genetic difference between two popula-
tions studied, Polish (30, 33) and Spanish (34). However, in my
opinion, another issue may be more important. Namely, it is
necessary to analyze carefully methods used for assessment of
particular parameters by both groups. For example, it appears
that the special disability scale, used by the authors testing
Spanish patients, is proper to estimate the level of disability,
but it may be of too low sensitivity to detect subtle cognitive
and behavioral changes. On the other hand, the modiﬁed Brief
Assessment Examination (BAE), used by the other group (30,
33), can be employed to detect only a very serious cognitive
disability, but it is useful in identiﬁcation of even small
improvement in severely affected patients. Thus, one might
expect very different results of studies on MPS patients if these
two tests are employed alternatively. This discrepancy high-
lights general problems with choosing the most appropriate tests
to assess efﬁcacy of any treatment of MPS patients, and
particularly MPS type III patients.
Different responses of various patients to GET IT, observed
in studies described above, may suggest that the employed dose
of genistein was not optimal, thus, some patients responded bet-
ter or worse to the treatment. Therefore, the next small study,
in which six MPS III patients were enrolled, was performed
with the dose of the soy isoﬂavone extract corresponding to 10,
and then 15 mg genistein per 1 kg of body weight daily (35).
Improvement in the urinary GAG level and hair morphology
was noted in all patients, and this improvement correlated with
the increase in the genistein dose (35).
Simultaneously to the open-label study with increased genis-
tein dose, a double-blinded, placebo-controlled clinical trial,
with 10 mg/kg/day genistein has been conducted. In this trial, a
cross-over has been performed after 6 months and 1 month
wash out, thus, each patient was treated for half a year. Six-
month follow-up study was then conducted for one group of
patients. Results of this trial indicated a signiﬁcant decrease of
GAG levels in urine and plasma, but no clinical improvement
could be detected (36). According to the authors’ suggestion
(36), perhaps the treatment was too short and the dose was too
low to observe signiﬁcant clinical changes, which might be
analogous to the results of short-term studies performed with
MPS type IIIB mice (compare refs. 27, 28, 30, 33–36).
All clinical studies described above were performed with
patients suffering from MPS type III. However, recent report
indicated that GET IT may also be beneﬁcial for other MPS
type(s), as improvement in joint mobility has been reported in
adult MPS type II patients treated with a soy isoﬂavone extract
(at the dose corresponding to 5 mg genistein/kg/day) for 6
months (37).
As soy isoﬂavone extracts are easily available in various
countries, it is not a surprise that, in the light of a lack of other
therapeutic options for MPS type III, many families started to
administer such extracts to children suffering from Sanﬁlippo
disease (MPS type III) on their own risk. However, it is impor-
tant to note that this may be a risky procedure, indeed. This is
not due to putative genistein-mediated adverse effects (in fact,
no adverse effects of GET IT were observed in experiments on
animals and clinical studies performed to date, see refs. 26–28,
30, 33–37), but because of the fact that various soy extracts
contain different amounts of isoﬂavones. In fact, among 7 soy
isoﬂavone products, randomly chosen and purchased in phar-
macy shops, only two contained amounts of genistein which
were equal or similar to those declared by manufacturers (38).
In some products, genistein occurred in amounts between 4 and
200 times lower than those indicated in information sheets (38).
Moreover, the products containing lower than expected
genistein amounts caused an increase, rather than decrease, in the
efﬁciency of GAG synthesis by MPS type III cells in vitro (38).
The summary of results of studies on animal models and
clinical trials, performed to date with GET IT for MPS, is pre-
sented in Table 2. Following conclusions can be drawn from
these studies. First, GET IT appears to be a safe treatment. Sec-
ond, genistein may be a compound causing improvement of at
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least some biological markers of MPS. Third, GET IT may lead
to either stabilization of the disease or even improvement in at
least some patients suffering from MPS types II and III. Fourth,
there is a huge variability in the response to GET IT among
patients. Fifth, doses of genistein signiﬁcantly higher than those
used in clinical studies performed to date may be considerably
more effective in GET IT for MPS. Sixth, it is an urgent need
for a double-blinded, placebo-controlled clinical trial with syn-
thetic genistein (like in studies on animals) used at high doses
(perhaps as high as 100–150 mg/kg/day, which were effective
in studies on MPS type IIIB mice and did not cause any adverse
effects).
Table 2
Summary of animal studies and clinical trials with the use of GET IT for MPS
Study type, subjects and duration Genistein dose Tested parameters Main results Reference
Animal study, MPS II mice,
duration: 10 weeks
5 or 25 mg/kg/day GAG levels in
various tissues
Reduction in GAG levels in
urine, liver, spleen, kidney,
heart, and brain (in some
animals)
26
Animal study, MPS IIIB mice,
duration: 8 weeks
5–160 mg/kg/day GAG storage in
liver and brain;
hair morphology
Reduction in GAG levels in
liver, but not in brain;
improved hair morphology
27
Animal study, MPS IIIB mice,
duration: 9 months
160 mg/kg/day GAG levels,
neuroimﬂammation,
secondary storage
and VAMP2
expression in brain;
behavior
Reduction of GAG levels,
neuroimﬂammation, storage
of gangliosides and
improved expression of
VAMP2 in brain; complete
correction of behavior
28
Open label clinical trial, 10 MPS
IIIA and IIIB patients, 1 year
5 mg/kg/day Urinary GAG level;
hair morphology;
cognitive functions
Decreased urinary GAG
levels; improved hair
morphology; improved
cognitive functions
30
Open label follow-up study, 8 MPS
IIIA and IIIB patients, 2 years
5 mg/kg/day Cognitive functions;
general and behavioral
symptoms
Improvement, stabilization or
deterioration of tested
parameters, depending on
patient
33
Open label clinical trial, 19 MPS
IIIA, IIIB and IIIC patients, 1 year
5 mg/kg/day Urinary GAG level;
hair morphology;
disability; general
clinical parameters
No decrease in urinary GAG
level; stabilization or
worsening in disability
score; improved hair
morphology; less frequent
infections and
gastrointestinal symptoms
34
Open-label clinical trial, 6 MPS
IIIA and IIIB patients, 1 year
10 and then
15 mg/kg/day
Urinary GAG level;
hair morphology
Reduced urinary GAG level;
improved hair morphology
35
Randomized, double-blinded,
placebo- controlled, cross-over
clinical trial, 30 MPS IIIA, IIIB
and IIIC patients, 19 months
10 mg/kg/day GAG levels in urine and
plasma; behavior; hair
morphology
Decreased levels of GAGs in
urine and plasma; no
signiﬁcant changes in
behavior; no changes in
hair morphology
36
Open-label clinical trial, 7 MPS II
patients, 6 months
5 mg/kg/day Joint range of motion Improved shoulder range of
motion; improved motion of
elbow and wrist (in some
patients); improved motion
of lower extremity joints
(in some patients)
37
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Secondary Roles of Genistein in Treatment of MPS
Although it appears that the primary action of genistein in
GET IT for MPS is inhibition of GAG synthesis through
impairment of EGF-mediated signal transduction (23), one may
ask whether it is the sole mechanism of efﬁcacy of this therapy.
This question is substantiated especially in the light of various
biological activities of genistein, described previously (for
reviews see refs. 39–41). Moreover, results of recent studies on
pathomechanisms of MPS led to proposals that not only primary
GAG storage but also secondary reactions are crucial for devel-
opment of symptoms characteristic for this disease. These
include secondary storage of gangliosides, accumulation of
hyperphosphorylated tau protein (P-tau), oxidative stress,
inﬂammation, cytotoxicity, and apoptosis (42–45).
Considering the complex pathomechanism of MPS and a
large spectrum of genistein activities, one may assume that this
isoﬂavone can be beneﬁcial in therapy of this disease due to
both its primary action as indirect GAG synthesis inhibitor and
its secondary, MPS-unspeciﬁc, effects. These include decreasing
of ganglioside storage (28), neuroprotection against P-tau-
induced neurotoxicity (46), attenuation of oxidative stress in
brain (47), prevention of neuroinﬂammation (48), and inhibition
of apoptosis in neuronal cells (49).
It might be intriguing that improvement in cognitive func-
tions was observed in some severely affected MPS type III
patients subjected to GET IT (30, 33). One might suppose
that already lost cognitive functions could not be restored
due to potentially irreversible neurodegeneration, which is
apparently not the case, as shown experimentally in studies
with animals and patients (28, 30, 33). However, ﬁndings
that genistein may stimulate expression of genes coding for
VAMP2 (28) and synaptophysin (50) may provide a rationale
for explaining such effects. These proteins are involved in
formation and functioning of synapses, and synthesis of
VAMP2 is impaired in MPS type III cells (28). Therefore, I
suggest that by facilitating synapse formation and function,
genistein is capable of not only protecting but also improving
cognitive abilities of MPS patients, even those in which
deterioration of brain functions was evident. Mechanisms
of genistein-mediated therapeutic action in MPS patients,
both conﬁrmed experimentally and putative, are summarized
schematically in Fig. 2.
CONCLUDING REMARKS AND FURTHER PERSPECTIVE
In vitro experiments with cell cultures and studies on animal
models suggested that GET IT may be a safe and effective ther-
apeutic option for patients suffering from MPS. However, clini-
cal trials, in which soy isoﬂavone extracts were used, suggested
a limited efﬁcacy. Still, GET IT remains a hope for MPS
patients, particularly those with severe neurological symptoms,
especially in the light of ﬁndings that indicated the complete
correction of behavior of MPS type IIIB mice. The main differ-
ence between highly efﬁcient action of genistein in MPS cell
cultures or MPS type IIIB mice and its limited efﬁcacy in clini-
cal trials was the use of high doses (up to 160 mg/kg/day) of
synthetic genistein in former studies and low doses (5–15 mg/
kg/day) of soy isoﬂavone extracts in latter studies. Therefore, I
suggest that efﬁcacy of GET IT might be potentially improved
when using relatively high doses of synthetic genistein. This
proposal can be tested in double-blinded, placebo-controlled
clinical trials. Moreover, one may speculate that combination of
GET IT with other treatments can be optimal for MPS patients
due to different mechanisms of action of therapeutic molecules
employed in various procedures, and possible cumulative posi-
tive effects. For example, combination of GET IT and ERT
might lead to rapid clearance of previously accumulated GAGs
by a recombinant enzyme in easily reached tissues and organs,
together with reduction of storage in those which are hardly
accessed by enzyme but reachable by small molecules (e.g., ge-
nistein), like brain or bones; at the same time, GET IT-mediated
impaired synthesis of GAGs could facilitate clearance of these
compounds by ERT even in the former group of tissues and
organs.
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Figure 2. Experimentally conﬁrmed and putative mechanisms
of genistein action in GET IT for MPS (the disease in which
degradation of glycosaminoglycans, GAGs, is impaired and
storage of these compounds is the primary cause of symptoms).
Gray arrows indicate stimulation, while blunt-ended black lines
indicate inhibition of particular reactions or processes.
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